Hepatitis research and treatment最新文献_第9页

Antiviral treatment for hepatitis C virus infection after liver transplantation. 肝移植后丙型肝炎病毒感染的抗病毒治疗。

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-11-01 DOI: 10.1155/2010/475746

Yasuhiko Sugawara, Sumihito Tamura, Norihiro Kokudo

引用次数: 5

Hypothyroidism in Noninterferon Treated-HCV Infected Individuals Is Associated with Abnormalities in the Regulation of Th17 Cells. 非干扰素治疗的hcv感染个体甲状腺功能减退与Th17细胞调节异常相关

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-03-08 DOI: 10.1155/2010/971095

Luis A Salazar, Xóchitl Garcia-Samper, Rafael Suarez-Carpio, María C Jimenez-Martínez, Erika P Rendón-Huerta, Felipe A Masso, Teresa I Fortoul, Luis F Montaño

{"title":"Hypothyroidism in Noninterferon Treated-HCV Infected Individuals Is Associated with Abnormalities in the Regulation of Th17 Cells.","authors":"Luis A Salazar, Xóchitl Garcia-Samper, Rafael Suarez-Carpio, María C Jimenez-Martínez, Erika P Rendón-Huerta, Felipe A Masso, Teresa I Fortoul, Luis F Montaño","doi":"10.1155/2010/971095","DOIUrl":"https://doi.org/10.1155/2010/971095","url":null,"abstract":"HCV-Ag-specific TH17 cells secrete IL17, a cytokine involved in autoimmune diseases and regulated by IL10 and TGF-b. 5-12% of patients with chronic HCV infection have hypothyroidism. We evaluated the role of these cytokines in this patients by determining serum concentration of TsH, T3, free T4, IL2, IL10, IL12, IL17, TGF-b, anti-TG, TPO, CCP, GBM, and cardiolipin antibodies in 87 chronically noninterferon treated HCV-infected patients. 20 patients (group A) had elevated TsH values (>5 μUI/ml) whereas the remaining 67 (group B) had normal values. The percentage of anti-TPO, TG, GBM, and cardiolipin antibodies in group A patients (33%, 41%, 5% and 5%, resp.) as well as IL17, IL2 and TGF-b concentrations (25 ± 23 pg/ml, 643 ± 572 pg/ml, and 618 ± 221 pg/ml, resp.) were significantly higher than group B. Abnormal Th17 regulation mediated by IL-2 and low TGF-b concentrations is associated with hypothyroidism in chronically-infected HCV patients.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":"2010 ","pages":"971095"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2010/971095","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29561142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. 聚乙二醇化干扰素加利巴韦林联合治疗的病毒学反应预测因子，包括病毒和宿主因素。

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-09-05 DOI: 10.1155/2010/703602

Namiki Izumi, Yasuhiro Asahina, Masayuki Kurosaki

引用次数: 17

Treatment of hepatitis C infections with interferon: a historical perspective. 干扰素治疗丙型肝炎感染:一个历史的观点。

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-09-06 DOI: 10.1155/2010/323926

Robert M Friedman, Sara Contente

引用次数: 19

Hepatitis C and kidney disease. 丙型肝炎和肾病。

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-08-17 DOI: 10.1155/2010/534327

Ashik Hayat, Ahmad Mitwalli

引用次数: 12

Evolution of interferon-based therapy for chronic hepatitis C. 干扰素治疗慢性丙型肝炎的进展

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-10-10 DOI: 10.1155/2010/140953

Chun-Hao Chen, Ming-Lung Yu

{"title":"Evolution of interferon-based therapy for chronic hepatitis C.","authors":"Chun-Hao Chen, Ming-Lung Yu","doi":"10.1155/2010/140953","DOIUrl":"https://doi.org/10.1155/2010/140953","url":null,"abstract":"Since 1986, interferon-alfa (IFN-α) monotherapy has been administered for patients with chronic hepatitis C (CHC). However, sustained response rate is only about 8% to 9%. Subsequent introduction of ribavirin in combination with IFN-α was a major breakthrough in the treatment of CHC. Sustained virological responses (SVRs) rate is about 30% in hepatitis C virus genotype 1 (HCV-1) patients, and is about 65% in HCV-2 or -3 patients. After 2000, pegylated interferon (PegIFN) much improved the rates of SVR. Presently, PegIFN-α-ribavirin combination therapy has been current standard of care for patients infected with HCV. In patients with HCV-1, treatment for 48 weeks is optimal, but 24 weeks of treatment is sufficient in HCV-2 or -3 infected patients. Clinical factors have been identified as predictors for the efficacy of the IFN-based therapy. The baseline factor most strongly predictive of an SVR is the presence of HCV-2 or -3 infections. Rapid virological response (RVR) is the single best predictor of an SVR to PegIFN-ribavirin therapy. If patients can't achieve a RVR but achieve a complete early virological response (cEVR), treatment with current standard of care can provide more than 90% SVR rate. HCV-1 patients who do not achieve an EVR should discontinue the therapy. Recent advances of protease inhibitor may contribute the development of a novel triple combination therapy.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":"2010 ","pages":"140953"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2010/140953","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29531614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19